Brazil’s Hypera Pharma announced on Monday, March 2, that it has signed a contract to buy a portfolio of 18 pharmaceutical products from Japan’s Takeda for US$825 million, reported Reuters.
The portfolio includes the painkiller Neosaldina, as well as drugs Dramin and Nesina. Hypera Pharma claims that following the transaction it will become Brazil’s top pharma company.
Hypera has secured a 3.5 billion reais (US$779.49 million) credit line to pay for the acquisition, which is contingent on antitrust authorities and shareholder approval of the deal.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Moves to Ban Non-Compete Agreements, Aiming to Boost Labor Mobility
Apr 23, 2024 by
CPI
Federal Judge Nods at $418M Deal in Real Estate Antitrust Suit
Apr 23, 2024 by
CPI
Mexican Watchdog Probes Amazon and Mercado Libre Over Loyalty Bundles
Apr 23, 2024 by
CPI
Competition Commission of India to Probe AI Landscape for Competition
Apr 23, 2024 by
CPI
Canada’s Agricultural Giants in Antitrust Spotlight
Apr 23, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI